CC BY
21o
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
THE CHANGE IN THE QT INTERVAL IS A MARKER OF THE SEVERITY
The number of patients with chronic liver diseases of various etiologies is increasing in the population, which lead to the development of cirrhosis, which affects other organs and systems, in particular, the cardiovascular system. The aim of the study was to evaluate changes in the QT interval in patients with cirrhosis of the liver and to identify the relationship with the severity of the hepatic process.
Material and methods. The study group included 30 patients with cirrhosis of the liver of various etiologies, hospitalized in the therapeutic department city hospital. The comparison group consisted of 30 patients without cirrhosis of the liver, hospitalized at the same time in the same department. The evaluation of clinical, laboratory and instrumental data ofpatients with the determination of the duration of the corrected QT interval according to the Bazett formula (QTs) was carried out. Statistical processing was carried out with the determination of the average, the error of the average, the reliability of the differences according to the criterion Student, correlation analysis using Pearson's r-test (Microsoft Excel, 2013).
Results and their discussion. Prolongation of the QT interval was found in patients with cirrhosis of the liver of various etiologies. A positive correlation was found between the severity of the Child-Pugh liver cirrhosis class and the magnitude of the QT interval. Conclusions. Prolongation of the QT interval in patients with cirrhosis of the liver can lead to the development of life-threatening arrhythmias and be the cause of sudden death of patients, and therefore it is necessary to regularly monitor electrocardiographic data in this group of patients.
Key words: cirrhosis of the liver, QT interval, cirrhotic cardiomyopathy.
INTRODUCTION
Cirrhosis of the liver remains a serious socio-economic and clinical-epidemiological health problem in all countries of the world and occupies a significant place in the structure of diseases of the digestive system. Recently, more and more researchers have been paying attention to hemodynamic disorders on the part of various organs and systems, significantly aggravating the course of liver
OF LIVER CIRRHOSIS
Khusainova Munira Alisherovna Gafforov Khudoyor Khudoyberdievich Uzokov Jurabek Bakhtiyorovich Tairova Zarangis Kamoliddinovna
Samarkand State Medical University
ABSTRACT
o
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
cirrhosis and negatively affecting the prognosis of the disease. In 2005, at the World Congress of Gastroenterologists in Canada, diagnostic criteria were proposed cirrhotic cardiomyopathy. However, the syndrome of cirrhotic cardiomyopathy has not yet been definitively classified and the mechanisms of development of myocardial dysfunction in cirrhosis are only partially known. Cirrhosis of the liver (CP) is one of the urgent problems of medicine of the last decade. This is due to a large increase in viral liver diseases, in particular caused by hepatitis B and C viruses. Portal circulation disorders trigger a cascade of autonomic, neurohumoral and metabolic reactions that cause changes in central hemodynamics, which exacerbates not only disorders of intrahepatic blood flow, but also leads to multiple organ extrahepatic disorders, including cirrhotic cardiomyopathy. Currently, more is being actively studied- heart disease in patients with viral cirrhosis of the liver (VCP), mechanisms of development of the main symptoms of cirrhotic cardiomyopathy, biochemical and electrophysiological changes of the heart, conditions for the occurrence of diastolic and systolic dysfunction, features of structural and functional changes in the myocardium. Meanwhile, the syndrome of cirrhotic cardiomyopathy has not yet been definitively classified, and many mechanisms for the development of myocardial dysfunction in patients with CP are unknown. The absence of these data indicates insufficient awareness of practitioners about changes in the cardiovascular system. Reports of deaths due to cardiac insufficiency during liver transplantation, transjugular intrahepatic portosystem bypass surgery and the imposition of surgical portacaval shunts in patients with cirrhosis suggest that myocardial dysfunction may progress with an increase in the volume of circulating- more blood. It is known that antiviral therapy in patients with chronic viral hepatitis and cirrhosis of the liver serves as a prevention of the development of liver failure and hepatic cell carcinoma. Currently, more convenient endpoints are used to evaluate the effectiveness of the therapy, which include suppression of virus replication, disappearance of the virus antigen, normalization of alanine aminotransferase activity, improvement of the histological picture of the liver, prevention of reactivation of infection after liver transplantation, as well as improvement of the quality of life of patients. The only drug with proven efficacy in the treatment of viral hepatitis and compensated viral cirrhosis of the liver is interferon used in combination with nucleoside analogues. The literature describes studies, as a result of which antiviral therapy leveled most of the structural and functional abnormalities of the cardiovascular system, improved the parameters of the functional state of the endothelium, and also contributed to the normalization of the number and frequency of occurrence of elevated levels of antimiocardial antibodies, with the exception of patients with mixed infection.
SJIF 2023 = 6.131 / ASI Factor = 1.7
(E)ISSN:2181-1784 www.oriens.uz 3(2), Feb., 2023
MATERIALS AND METHODS
All these data dictate the need for a thorough examination of the cardiovascular system in patients with cirrhosis of the liver, including performing an electrocardiographic study with an assessment of cardiac arrhythmias.
Table 1. Clinical and laboratory indicators
Indicator Cirrhosis of Chronic
the liver (n =30) hepatitis (n= 10)
Ascites 90% 0
Average AST value (units) 247.9±3.2 209.9±2.0
The average ALT value (units) is 217.9±1.2 205.9±0.9
The average diameter of the portal vein 14.2±0.2 9.4±0.3
(mm) is
Complaints from the cardiovascular 8 0
system (%)
Table 2. Electrocardiography data
ECG report (% of the number of patients) Cirrhosis of the liver (n =30) Chronic hepatitis (n= 10)
Sinus tachycardia 10 50
Sinus bradycardia 5 20
AV blockade 1 st 25 0
Atrial extrasystoles 25 15
Ventricular extrasystoles 30 15
Blockade of the left leg of the Gis beam 5 0
40 patients were included in the study. The first group consisted of patients with cirrhosis of the liver - 30 patients,the second group - 10 patients with chronic hepatitis. Patients diagnosed with cirrhosis of the liver were divided into Child -Pugh classes, class A was represented in 10% of cases, class B - 50%, class C - 40%. In the first group, men made up 25 people (62.5%), respectively, women - 15 people (37.5%). In the second group, men made up 4 people (40%), women - 6 people (60%). Among patients with cirrhosis of the liver, the average age was 51.2±2.0 in the category of patients with chronic hepatitis - 43.4 ± 1.0.In the structure of the etiology
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
of cirrhosis of the liver in the first place alimentary toxic (70%), in the second place -the outcome of viral hepatitis (30%). Patients who abuse alcohol, have cardiovascular, mental and systemic diseases were excluded from the study. All patients underwent a standard clinical and laboratory examination. When analyzing the ECG, the adjusted QT interval was calculated using the Bazett formula. QTc = (Q-T measured) / (V(R-R measured)).
The duration of the QTc interval in patients with cirrhosis of the liver (442.3±3.2 ms) was significantly longer than in patients with hepatitis (411.4±2.7) (p<0.001). It was revealed in patients of the first group an increasing prolongation of the YEs interval as the severity of liver cirrhosis worsened. The duration of the Ec interval was 409±1.8 ms in Class A, 431±2.6 ms in patients with cirrhosis of class B according to Child -Pugh, and 442.3±1.1 ms in class C according to Child -Pugh (p<0.001).
When assessing the duration of the QTc interval in patients with cirrhosis of the liver, attention is drawn to the differences between the duration of this interval depending on the etiology of liver cirrhosis. In patients with liver cirrhosis of alimentary-toxic genesis, the QTc interval was 432.3±1.2 ms, in patients with viral etiology of liver cirrhosis - 439±1.6 ms (p<0.001).
CONCLUSION
Cirrhosis of the liver affects all systems of the human body, including the cardiovascular system. In cirrhosis of the liver, rhythm disturbances are more common than in chronic hepatitis; the most frequent rhythm disturbances in cirrhosis of the liver according to ECG data is ventricular extrasystole. It was found that the duration of the Qt interval is significantly longer in patients with cirrhosis of the liver, which indicates a systemic violation of metabolic processes and involvement of all systems in this category of patients. These changes "dictate" a detailed study of the cardiovascular systems in patients with cirrhosis of the liver.
REFERENCES
1. Yusufovich, N. F., & Khabibovna, Y. S. (2022). MEDICAL AND SOCIAL ASPECTS OF PREVENTION AMONG STUDENTS IN THE CONDITIONS OF COVID-19 PANDEMICS. Web of Scientist: International Scientific Research Journal, 3(12), 860-865.
2. Назаров, Ф. Ю., & Ярмухамедова, С. Х. (2022). Медико-социальные аспекты профилактики среди студенческой молодежи в условиях пандемии COVID-19. Science and Education, 3(12), 256-263.
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
3. Habibovna, Y. S., & Kayumovna, A. S. (2021). Study of the functional state of the myocardium in patients with hypertension. Web of Scientist: International Scientific Research Journal, 2(11), 170-174.
4. Nizamitdinovich, X. S., & Toshtemirovna, E. M. (2021). Pathogenetic relationship of metabolic disorders in patients with arterial hypertension and diabetes type 2. Web of Scientist: International Scientific Research Journal, 2(11), 156-160.
5. Ибадова, О., Махматмурадова, Н., & Курбанова, З. (2020). ПОТЕНЦИАЛЬНЫЕ ФАКТОРЫ РИСКА В РАЗВИТИИ И
ПРОГРЕССИРОВАНИИ неспецифической интерстициальной
ПНЕВМОНИИ. Журнал кардиореспираторных исследований, 1(1), 72-76.
6. Ибадова, О. А., Курбанова, З. П., & Шодиев, О. О. (2021). ФАКТОРЫ РИСКА В ПРОГРЕССИРОВАНИИ НЕСПЕЦИФИЧЕСКОЙ ИНТЕРСТИЦИАЛЬНОЙ ПНЕВМОНИИ. Достижения науки и образования, (8 (80)), 101-107.
7. Ибадова, О. А., & Шодикулова, Г. З. (2022). РОЛЬ СУРФАКТАНТНОГО ПРОТЕИНА А (SP-A) В ПРОГНОЗЕ ПРОГРЕССИРОВАНИЯ И ИСХОДА НЕСПЕЦИФИЧЕСКОЙ ИНТЕРСТИЦИАЛЬНОЙ ПНЕВМОНИИ. Достижения науки и образования, (1 (81)), 66-72.
8. Yarmukhamedova, S., Nazarov, F., Mahmudova, X., Vafoeva, N., Bekmuradova, M., Gaffarov, X., ... & Xusainova, M. (2020). Features of diastolic dysfunction of the right ventricle in patients with hypertonic disease. Journal of Advanced Medical and Dental Sciences Research, 8(9), 74-77.
9. Yarmukhamedova, S., Nazarov, F., Mahmudova, X., Vafoeva, N., Bekmuradova, M., Gafarov, X., ... & Xusainova, M. (2020). Study of indicators of intracardial hemodynamics and structural state of the myocardium in monotherapy of patients with arterial hypertension with moxonidin. Journal of Advanced Medical and Dental Sciences Research, 8(9), 78-81.
10. Akbarov, A. T. U., Feruz Yusufovich, N., & Xusseinova, M. A. (2021). Features Of Intensive Therapy For Preeclampsia And Eclampsia. The American Journal of Medical Sciences and Pharmaceutical Research, 3(01), 124-130.
11. Khusainova, M. A., Toirov, D. R., Khaydarov, S. N., & Kamolova, D. D. (2023). MORPHOFUNCTIONAL PARAMETERS OF THE HEART IN WOMEN SUFFERING FROM ESSENTIAL ARTERIAL HYPERTENSION IN POSTMENOPAUSE AND ON THE BACKGROUND OF TREATMENT. Oriental renaissance: Innovative, educational, natural and social sciences, 3(1), 322-330.
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
12. Nizamitdinovich, K. S., & Alisherovna, K. M. (2022). Quality of Life in Patients with Chronic Heart Failure, After Cardiac Resynchronization Therapy. Texas Journal of Medical Science, 14, 168-173.
13. Rustamovich, T. D., Alisherovna, K. M., Nizamitdinovich, K. S., & Djamshedovna, K. D. (2022). Gastrointestinal Conditions in Rheumatoid Arthritis Patients. Texas Journal of Medical Science, 15, 68-72.
14. Rustamovich, T. D., & Khasanovich, B. D. (2022). CHARACTERISTICS OF HEART FUNCTIONAL DISORDERS IN GOUT DISEASE. Galaxy International Interdisciplinary Research Journal, 10(5), 551-558.
15. Хусаинова, М. (2021). Chronic Heart Failure In Patients With Early Rheumatoid Arthritis. Журнал кардиореспираторных исследований, 2(4), 67-69.
16. Хусаинова, М. А. (2022). OZONETHERAPY IN RESTORATIVE TREATMENT PATIENTS WITH CORONARY HEART DISEASE. Журнал кардиореспираторных исследований, 3(4).
17. Nizamitdinovich, K. S., Alisherovna, K. M., Erkinovna, K. Z., & Davranovna, M. K. (2022). Heart Lesions in Rheumatological Diseases. Texas Journal of Medical Science, 13, 91-94.
18. Davranovna, M. K., Alisherovna, K. M., Erkinovna, K. Z., & Nizamitdinovich, K. S. (2022). Assessment of the Quality of Life of Patients with Coronary Heart Disease. The Peerian Journal, 11, 44-50.
19. Totlibayevich, Y. S., Alisherovna, K. M., Xudoyberdiyevich, G. X., & Toshtemirovna, E. M. M. (2022). Risk Factors for Kidney Damage in Rheumatoid Arthritis. Texas Journal of Medical Science, 13, 79-84.
20. Erkinovna, K. Z., Alisherovna, K. M., Davranovna, M. K., & Nizamitdinovich, K. S. (2022). Correction of Cytokine Imbalance in the Treatment of Stable Angina Pectoris. The Peerian Journal, 11, 64-70.
21. Rustamovich, T. D., Alisherovna, K. M., Baxtiyorovich, U. J., & Abdurakhmonovich, M. M. (2022). Painless Cardiac Ischemia in Women with Rheumatoid Arthritis. Texas Journal of Medical Science, 13, 95-98.
22. Toshtemirovna, E. M. M., Alisherovna, K. M., Totlibayevich, Y. S., & Xudoyberdiyevich, G. X. (2022). Anxiety Disorders and Coronary Heart Disease. The Peerian Journal, 11, 58-63.
23. Xudoyberdiyevich, G. X., Alisherovna, K. M., Toshtemirovna, E. M., & Jamshedovna, K. D. (2022). Features of portal blood circulation and echographic structure of the liver in patients with chronic heart failure. Web of Scientist: International Scientific Research Journal, 3(5), 576-581.
o
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
24. Toshtemirovna, E. M. M., Alisherovna, K. M., Totlibayevich, Y. S., & Muxtorovna, E. M. (2022). Hearts In Rheumatoid Arthritis: The Relationship With Immunological Disorders. Spectrum Journal of Innovation, Reforms and Development, 4, 34-41.
25. Nizamitdinovich, K. S., & Alisherovna, K. M. (2022). Quality of Life in Patients with Chronic Heart Failure, After Cardiac Resynchronization Therapy. Texas Journal of Medical Science, 14, 168-173.
26. Jamshedovna, K. D., Alisherovna, K. M., Davranovna, M. K., & Xudoyberdiyevich, G. X. (2022). Epidemiology And Features Of Essential Therapy Hypertension In Pregnant Women. Web of Scientist: International Scientific Research Journal, 3(5), 606-611.
27. Toshtemirovna, E. M. M., Alisherovna, K. M., Totlibayevich, Y. S., & Duskobilovich, B. S. (2022). THE VALUE OF XANTHINE IN CHRONIC HEART FAILURE. Spectrum Journal of Innovation, Reforms and Development, 4, 24-29.
28. Jamshedovna, K. D., Alisherovna, K. M., Erkinovna, K. Z., & Davranovna, M. K. (2022). LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN PREGNANT WOMEN WITH PRE-ECLAMPSIA WITHOUT PROTEINURIA. Spectrum Journal of Innovation, Reforms and Development, 10, 135-140.
29. Xudoyberdiyevich, G. X., Alisherovna, K. M., Toshtemirovna, E. M. M., & Totlibayevich, Y. S. (2022). Characteristics Of Neuropeptides-Cytokines in Patients with Cardiovascular Pathology Occurring Against the Background of Anxiety and Depressive Disorders. The Peerian Journal, 11, 51-57.
30. Xudoyberdiyevich, G. X., Alisherovna, K. M., Davranovna, M. K., & Toshtemirovna, E. M. M. (2022). FEATURES OF HEART DAMAGE IN PATIENTS WITH VIRAL CIRRHOSIS OF THE LIVER. Spectrum Journal of Innovation, Reforms and Development, 10, 127-134.
31. Toshtemirovna, E. M. M., Alisherovna, K. M., Erkinovna, K. Z., & Xudoyberdiyevich, G. X. (2022). DIAGNOSIS OF CIRRHOTIC CARDIOMYOPATHY. Spectrum Journal of Innovation, Reforms and Development, 10, 141-147.
32. Alisherovna, K. M., Kulmuxammatovich, Y. U., Boymamatovna, E. F., & Azzamjonovich, N. A. (2023). OZONETHERAPY FOR CORONARY HEART DISEASE. Web of Scientist: International Scientific Research Journal, 4(1), 93-99.
33. Yarmatov, S. T., & Xusainova, M. A. (2021). BRONXIAL ASTMA MAVJUD BO'LGAN BEMORLARDA GASTROEZOFAGIAL REFLYUKS KASALLIGI DIAGNOSTIKASI VA OLIB BORISH ALGORITMI. Scientific progress, 2(2), 208213.
o
SJIF 2023 = 6.131 / ASI Factor = 1.7
3(2), Feb., 2023
34. Khusainova, M. A. (2023). CYSTATIN C IS AN EARLY MARKER OF DECREASED KIDNEY FUNCTION. Oriental renaissance: Innovative, educational, natural and social sciences, 3(1), 485-490.
35. Zikiryayevna, S. G., Muxtorovna, E. M., Jurakulovich, U. I., & To'raqulovna, Q. S. (2022). PAINLESS CARDIAC ISCHEMIA IN WOMEN WITH RHEUMATOID ARTHRITIS. Web of Scientist: International Scientific Research Journal, 3(10), 397-
405.
